State-owned Chinese animal-health company (Sinopharm) making veterinary vaccines and animal pharmaceuticals, plus livestock breeding.
State-owned Chinese animal-health company (Sinopharm) making veterinary vaccines and animal pharmaceuticals, plus livestock breeding.
Sells vaccines both to governments, which buy compulsory-immunisation vaccines through bidding rounds, and to farms and distributors in the open market, so state policy decides a large part of volumes. It sits under a state-owned group that spans animal health.
In one line: A Chinese Zoetis/Elanco for livestock.
Moat: narrow (regulatory licence, scale, distribution). State-backed veterinary vaccine licenses and a nationwide distribution network for disease-control programs.
Headquarters: Beijing, China · Employees: 3,996
Size China Animal Husbandry Industry (600195.SS) is a China Health Care company (Biotechnology) with a market value of $921M, the 2320th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.02 on 18 Nov 2026.
Performance Over six months the shares fell 16.4%, against -15.8% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 1.1% over the last twelve months (peer median +2.0%); the operating margin is 1.8% (peer median -25.0%).
Valuation It trades at 41.5× forward earnings against a peer median of 29.2× (3rd most expensive of 7).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.9 points below its cost of capital (5.8% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.34B | CN¥6.19B | CN¥5.98B | CN¥5.37B | CN¥5.88B |
| Revenue growth | — | +4% | +11% | -9% | — |
| Gross profit | CN¥1.34B | CN¥973M | CN¥827M | CN¥926M | CN¥1.16B |
| EBITDA | n/a | CN¥380M | CN¥357M | CN¥504M | CN¥634M |
| Net income | CN¥4.23M | CN¥171M | CN¥70.9M | CN¥403M | CN¥550M |
| Free cash flow | CN¥662M | CN¥962M | -CN¥16.0M | -CN¥246M | -CN¥607M |
| Capital expenditure | CN¥217M | CN¥241M | CN¥459M | CN¥643M | CN¥464M |
| Total debt | CN¥2.51B | CN¥1.66B | CN¥1.34B | CN¥1.46B | CN¥451M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Animal Husbandry Industry 600195.SS | $921M | -16% | +1% | 2% | 41.5× | 6.1% |
| Zoetis ZTS | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% |
| Elanco Animal Health ELAN | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% |
| Pulike Biological Engineering 603566.SS | $449M | -21% | -9% | 5% | 23.2× | 4.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600195.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.1% | -7.9% | 9th lowest of 21 |
| 6-month return | -16.4% | -15.8% | 11th highest of 21 |
| Distance from 52-week high | -33.3% | -40.8% | 5th highest of 21 |
| Revenue growth (TTM) | +1.1% | +2.0% | 8th lowest of 17 |
| Operating margin | 1.8% | -25.0% | 5th highest of 17 |
| Forward P/E | 41.5× | 29.2× | 3rd most expensive of 7 |
| Growth the price implies (Req g, 7 yrs) | 6.1% | 9.2% | 2nd least demanding of 6 |
| Growth delivered (Del g) | +4.4% | -5.8% | highest of 6 |
| Hurdle (Req g minus delivered) | +1.7 pp | +20.1 pp | least demanding of 6 |
| ROIC minus cost of capital | -2.9 pp | -11.2 pp | 5th highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 41.5× | 6.1% | +4.4% |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 92.6× | 39.6% | -16.6% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | n/a | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 21.6× | 9.2% | +2.3% |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 143.0× | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 29.9× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | n/a | n/a | n/a |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | n/a | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 28.4× | 14.3% | -5.8% |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | n/a | 4.8% | -32.3% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | n/a | n/a | n/a |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 19.4× | 7.8% | +2.4% |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | n/a | n/a | n/a |